Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 10, 2017, Pages 893-895

  Watkins, Richard R ^a,b   Deresinski, Stan ^c  

^a Northeast Ohio Medical University   (United States)

^b Infectious Disease Section   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; beta lactam beta lactamase inhibitors; blood stream infections; CRE; ESBL

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFTOLOZANE PLUS TAZOBACTAM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DRUG EFFICACY; DRUG EXCRETION; DRUG PENETRATION; DRUG URINE LEVEL; EDITORIAL; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; MORTALITY RATE; NONHUMAN; BETA-LACTAM RESISTANCE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECT; ENTEROBACTERIACEAE; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS;

EID: 85029701701     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1380519     Document Type: Editorial

References (23)

1. Weiner LM, Fridkin SK, Aponte-Torres Z, et al. Vital signs: Preventing antibiotic-resistant infections in hospitals. MMWR Morb Mortal Wkly Rep. 2016;65:235–241.
2. Schwaber MJ, Navon-Venezia S, Kaye KS, et al. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257–1262.
3. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1987–1994.
4. Paterson DL., Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460–463.
5. Pitout JD, Laupland KB., Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166.
6. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151–1161.
7. Potter RF, D’Souza AW, Dantas G. The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat. 2016;29:30–46.
8. Tamma PD, Villegas MV. Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population. Antimicrob Agents Chemother. 2017;61(8):e01094-e01117.
9. López-Cerero L, Picón E, Morillo C, et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect. 2010;16:132–136.
10. Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–1325.
11. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60:4159–4169.
12. Gudiol C, Royo-Cebrecos C, Abdala E, et al. Efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-β-lactamase-producing Enterobacteriaceae in hematological patients with neutropenia. Antimicrob Agents Chemother. 2017;61(8).
13. Muhammed M, Flokas ME, Detsis M, et al. Comparison between carbapenems and β-lactam/β-lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. Open Forum Infect Dis. 2017;4(2):ofx099.
14. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31–37.
15. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother. 2003;47:1643–1646.
16. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48:4574–4581.
17. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129:242–258.
18. Retamar P, López-Cerero L, Muniain MA, et al. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2013;57:3402–3404.
19. Berkhout J, Melchers MJ, van Mil AC, et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015;59:2299–2304.
20. Liu P, Li X, Luo M, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis. Microb Drug Resist. 2017 Jul 27. [Epub ahead of print].
21. Madueño A, Gonzalez Garcia J, Aguirre-Jaime A, et al. A hospital-based matched case-control study to identify risk factors for clinical infection with OXA-48-producing Klebsiella pneumoniae in rectal carriers. Epidemiol Infect. 2017 Jul 17;1–5. Epub ahead of print.
22. Okamoto K, Lin MY, Haverkate M, et al. Modifiable risk factors for the spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae among long-term acute-care hospital patients. Infect Control Hosp Epidemiol. 2017;38:670–677.
23. Harris PN, Peleg AY, Iredell J, et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials. 2015;16:24.